| Phase | Tb vaccine | Tb vaccine type |
| Phase I | AdAg85A | Viral vectored (Adenovirus serotype 5 expressing Ag85A) |
| MTBVAC | Attenuated Mycobacterium tuberculosis strain (Attenuated M. tuberculosis clinical isolate with ESAT6 & CFP10 & independent stable genetic deletions of phoP & fadD26 genes) | |
| ID93 + GLA-SE | Protein/adjuvant (Fusion Rv1813, Rv2608, Rv3619, Rv3620 with GLA-SE adjuvant) | |
| DAR 901 | Mycobacterial—whole cell or extract (Agar-grown SRL172 by scalable, broth-grown manufacturing technique) | |
| TB/FLU-04L | Viral vectored (Attenuated replication- deficient influenza virus vector expressing antigens Ag85A & ESAT-6) | |
| Phase IIa | VPM 1002 | Recombinant BCG (rBCG vaccine with listeriolysin O encoding gene) |
| RUTI | Mycobacterial, whole cell or extract (Polyantigenic liposomal vaccine of detoxified, fragmented M. tuberculosis) | |
| H56: IC31 | Protein/adjuvant (Fusion protein of Ag85B, ESAT-6, latent Rv2660c with IC31 adjuvant) | |
| H4: IC31 | Protein/adjuvant (H4 antigen, IC31 adjuvant) | |
| MVA85A | Viral vectored (Recombinant replication-deficient modified Vaccinia virus Ankara expressing Ag85A) | |
| M72 + AS01E | Protein/adjuvant (Fusion protein Mtb32A & Mtb39A, AS01E adjuvant) | |
| Phase III | Vaccae | Mycobacterial, whole cell or extract (Heat-killed M. vaccae) |